Immunotherapy Advances Journal

Immunotherapy Advances publishes from discovery through to clinical trials - now more accessible than ever thanks to read & publish. Make your science count beyond the lab bench. Read more about read and publish here: bit.ly/4ksUbHJ

Phase 3 data show 20% subcutaneous Ig (Ig20Gly) given weekly or every 2 weeks maintains protective IgG levels (>8 g/L) with a favourable safety profile in Japanese patients with PIDs. Flexible dosing with promising clinical impact. doi.org/10.1093/immadv… #Immunology

Study shows comparable cellular immunogenicity in chronic plaque psoriasis patients receiving continuous Humira® or repeated switching with biosimilar AVT02, supporting interchangeability findings. doi.org/10.1093/immadv… #Psoriasis #Biosimilars #Immunology

Tracking engineered T cells after infusion is crucial. This study shows a rapid whole-blood assay can assess TCR T cell function in vivo, with cytokine responses reflecting dose in HBV-related liver cancer. 🔗 doi.org/10.1093/immadv… #Immunotherapy #TCells #Immunology

🔬 Regulatory B cells are key to immune balance, but their role in autoimmune disease is highly variable. This highlights the need for more personalised approaches to treatment. 📖 doi.org/10.1093/immadv…

Submissions still open for the CD40 turns 40 Special Collection, exploring four decades of CD40 biology and its impact on immunotherapy across cancer, autoimmunity, and more 🧬 Submit by end of June 2026. Learn more about submitting here: academic.oup.com/immunotherapya… #Immunology

Population modelling reveals key drivers of CAR T-cell dynamics in lymphoma patients, highlighting roles for lymphodepletion, tumour burden, and cytokines like IL-15/IL-7 🧬 🔗 doi.org/10.1093/immadv… #Immunotherapy #CARTcells #CancerResearch

A high-affinity ImmTAC® bispecific efficiently redirects T cells to target PRAME+ tumour cells, even at very low antigen levels, highlighting its promise across multiple cancers 🧬 🔗 doi.org/10.1093/immadv… #Immunotherapy #CancerResearch #Tcells #OpenAccess

A simple whole-blood assay enables rapid, in vivo monitoring of engineered TCR T cell function, capturing cytokine responses post-transfer without complex processing. A practical step for tracking cell therapy performance. 🧬 doi.org/10.1093/immadv… #Immunotherapy #Tcells

A step forward in evolving cell therapies for AML: integrating TCR, CAR, BiTE, and safety switch into a single engineered T cell highlights how the field is moving toward multi-functional, adaptable designs to overcome tumor complexity. doi.org/10.1093/immadv… #Immunotherapy

📢 New open‑access study shows MAGE‑A4‑specific TCR‑NK cells combine innate NK killing with targeted TCR activity ,offering a potent, safe, “off‑the‑shelf” strategy for solid tumors. 🔗 doi.org/10.1093/immadv…

Attending #CIMT2026? Immunotherapy Advances is welcoming submissions to its Cancer Vaccines – Global Advances collection (deadline extended to July 2026). Hear more from Guest Editor Prof Lennard Lee, speaking at CIMT today at 14:00. #CancerVaccines #Immunotherapy

📢 Open‑access study shows fSCIG 10% maintains stable IgG levels in children with PID and supports every‑3–4‑week dosing. 🔗 doi.org/10.1093/immadv…

Open‑access research shows that M2 macrophages help alleviate asthma in mice by promoting IL‑10⁺ B‑cell responses, with evidence pointing to TGF‑β and metabolic pathways as key regulators. Insights into immune regulation in asthma. 👉 doi.org/10.1093/immadv… 🫁#WorldAsthmaDay

Marking World Immunization Week 2026 with a call for papers for Cancer Vaccines: Global Advances, highlighting cutting‑edge research in personalised and off‑the‑shelf cancer vaccines. Submissions open until April 2026. 🧬 #WorldImmunizationWeek #CancerVaccines #CallForPapers

🧬 Open‑access study shows how spatial immune architecture and macrophage polarization shape immunotherapy responses in mismatch repair–deficient colorectal cancer, helping explain why metastatic lesions respond differently. 👉 doi.org/10.1093/immadv… #Immunotherapy

🧬 In advanced melanoma, certain immune‑related adverse events, including rheumatic, endocrine and sarcoidosis‑like effects, are associated with improved survival following PD‑1 inhibition, often alongside lower corticosteroid use. 👉 doi.org/10.1093/immadv…

Can blood‑based T‑cell markers predict PD‑1 therapy response in melanoma? This study suggests yes, highlighting CD8⁺ proliferation in responders and CTLA‑4⁺ Tregs in non‑responders. Read here📄 bit.ly/4pw1rVL

How Streptococcus pneumoniae interacts with innate immunity matters. New open‑access research shows neuraminidase A (NanA) shapes immune sensing and phagocytic clearance in microglia and macrophages, with implications for pneumococcal meningitis. vist.ly/4y22j

Open‑access review explores how targeting monocyte dynamics could offer new therapeutic approaches for multiple sclerosis, with insights from experimental models highlighting monocyte plasticity and inflammation resolution. doi.org/10.1093/immadv…

New open‑access paper outlines how the UK Vaccine Innovation Pathway is accelerating cancer vaccine trials across the NHS, boosting recruitment, streamlining delivery, and supporting equitable access. doi.org/10.1093/immadv…